11,261 Shares in Teladoc Health, Inc. (NYSE:TDOC) Bought by Innealta Capital LLC

Innealta Capital LLC acquired a new position in shares of Teladoc Health, Inc. (NYSE:TDOC) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 11,261 shares of the health services provider’s stock, valued at approximately $110,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. ICA Group Wealth Management LLC purchased a new position in Teladoc Health in the fourth quarter valued at about $28,000. Hexagon Capital Partners LLC grew its position in shares of Teladoc Health by 204.4% during the fourth quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock worth $34,000 after buying an additional 1,065 shares in the last quarter. GAMMA Investing LLC bought a new stake in shares of Teladoc Health in the fourth quarter worth $41,000. Principal Securities Inc. bought a new stake in shares of Teladoc Health in the 4th quarter worth about $45,000. Finally, SageView Advisory Group LLC bought a new position in Teladoc Health during the 1st quarter worth approximately $48,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Teladoc Health Trading Up 0.8 %

Shares of NYSE:TDOC traded up $0.06 during midday trading on Friday, reaching $7.16. The company had a trading volume of 8,648,213 shares, compared to its average volume of 5,486,465. The company has a fifty day simple moving average of $8.56 and a two-hundred day simple moving average of $11.99. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -5.09 and a beta of 0.93. Teladoc Health, Inc. has a 1-year low of $6.76 and a 1-year high of $23.19. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.62 and a current ratio of 1.66.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, July 31st. The health services provider reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.08. Teladoc Health had a negative net margin of 38.54% and a negative return on equity of 10.25%. The company had revenue of $642.44 million during the quarter, compared to analysts’ expectations of $649.34 million. Research analysts predict that Teladoc Health, Inc. will post -0.7 earnings per share for the current year.

Insider Transactions at Teladoc Health

In other news, COO Michael Willem Waters sold 6,053 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $49,271.42. Following the transaction, the chief operating officer now owns 74,214 shares in the company, valued at approximately $604,101.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Vidya Raman-Tangella sold 3,857 shares of the business’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $8.14, for a total transaction of $31,395.98. Following the transaction, the insider now owns 33,667 shares in the company, valued at approximately $274,049.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Michael Willem Waters sold 6,053 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $8.14, for a total transaction of $49,271.42. Following the completion of the sale, the chief operating officer now owns 74,214 shares of the company’s stock, valued at approximately $604,101.96. The disclosure for this sale can be found here. Insiders sold a total of 42,880 shares of company stock valued at $355,689 over the last quarter. Company insiders own 0.95% of the company’s stock.

Analyst Ratings Changes

TDOC has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating for the company in a research note on Friday, August 2nd. JPMorgan Chase & Co. cut their target price on shares of Teladoc Health from $16.00 to $9.00 and set a “neutral” rating on the stock in a report on Monday. Piper Sandler dropped their price target on Teladoc Health from $25.00 to $10.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. TD Cowen reduced their price objective on Teladoc Health from $15.00 to $9.00 and set a “hold” rating for the company in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 target price on shares of Teladoc Health in a research report on Tuesday, August 20th. Fourteen research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Teladoc Health has an average rating of “Hold” and a consensus target price of $12.44.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.